Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novuspharma Phase II prostate cancer data

Novuspharma (NMerc:NOV) said that in a Phase II trial, 15 of 61 evaluable patients with hormone resistant

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE